Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Christopher Ronkar (NPI 1992810956)

Field	Value
Entity Type	Individual
Organization	Christopher Ronkar
Address	8421 Plum Dr
City	Urbandale
State	IA
ZIP	50322
Taxonomy	Rheumatology Physician
NPI Enumerated	August 20, 2006

Payer Source	Total Paid
Medicare	$1.5M
Medicaid	$0

Key Findings

CHRISTOPHER RONKAR is a Rheumatology Physician based in URBANDALE, IA with an NPI enumerated on 2006-08-20 (~20 years ago), indicating an established clinical presence; the provider’s lifetime Medicare revenue on file is $1.5M and there is no Medicaid billing on file, so this profile is effectively single‑payer Medicare.

Revenue is highly concentrated in a small set of injectable biologic drugs: the precomputed top three Medicare codes (J0897, J0129, J9312) account for 62.0% of the provider’s total Medicare revenue, with J0897 representing 28.5%, J0129 19.9%, and J9312 13.6% of Medicare revenue.

The code mix points to a service model built around on‑site biologic and infusion therapy plus bone health management: high‑revenue drug codes (J0897 denosumab, J0129 abatacept, J9312 rituximab) and infusion administration/chemotherapy codes (96413, 96401, 96415) appear alongside DXA/osteoporosis codes (77080, J3111 romosozumab), suggesting combined rheumatology and infusion/osteoporosis services with in‑clinic drug administration and monitoring.

J0897 (denosumab) is an outlier in national rankings — listed as an “extreme outlier, far above typical national volume” and ranked #189 of 10057 providers (98th percentile) — indicating the provider is a nationally prominent administrator of this specific drug compared with peers. In contrast, J0129 (abatacept) and J9312 (rituximab) are described as “typical, unremarkable volume” at their national ranks (#569 of 1221 and #154 of 317 respectively), signifying more modest competitive positions for those agents.

Evaluation and management activity shows relatively high office visit billing compared with peers: 99213 is flagged as “notably above typical national volume” (rank #21500 of 457151, 95th percentile) and 99214 is at the 93rd percentile, which together suggest a sustained ambulatory clinic workload that complements infusion services.

Ancillary diagnostics and monitoring are present but represent a small share of revenue: DXA (77080) and bone‑score imaging (77089) appear on the list alongside routine labs (82565, 82310, 84460, 84450), consistent with ongoing osteoporosis and immunomodulatory treatment monitoring rather than revenue drivers.

Although the practice posts meaningful absolute claim counts for multiple high‑use drugs (e.g., J0897, J0717, J0129), most non‑top‑3 line items are described as typical or modest participants in national distributions; this pattern suggests a specialized infusion‑centric business that relies heavily on a few high‑impact biologic codes rather than a broadly diversified payor/product mix.

The payer concentration (Medicare $1.5M vs. Medicaid none (no Medicaid billing on file)) creates operational exposure to Medicare policy and utilization shifts for biologic administration; any changes in Medicare coverage or reimbursement for the dominant codes (notably J0897) could materially affect total revenues given the 62.0% concentration in the top three codes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

50 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0897	Injection, denosumab, 1 mg	23,640	$20	$425.5K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	8,730	$30	$296.6K
J9312	Injection, rituximab, 10 mg	3,180	$60	$203.5K
J3111	Injection, romosozumab-aqqg, 1 mg	14,910	$10	$119.3K
J1602	Injection, golimumab, 1 mg, for intravenous use	9,500	$10	$104.5K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	23,800	$1	$95.2K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	2,450	$30	$63.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	600	$80	$49.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	570	$60	$32.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	320	$100	$30.3K

Showing 1–10 of 50

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 50 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Christopher Ronkar — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

50 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	5	20	5,950	$30	$218.3K
J9312	3	10	3,190	$60	$198.4K
J1602	10	10	13,010	$10	$153.6K
J3111	6	20	12,180	$10	$112K
J0717	8	20	23,500	$1	$93.9K
J1745	14	20	3,460	$30	$92.3K
J0897	4	190	1,920	$20	$74.1K
96413	24	80	210	$90	$24K
99214	357	4,690	100	$70	$14.4K
99490	162	330	130	$40	$9K

Showing 1–10 of 50

Related Providers

Other providers that share a Tax Identification Number (TIN) with Christopher Ronkar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Robert Behrens	IA	Medical Oncology Physician	$5.2M	$0
Matthew Mcknight	IA	Foot & Ankle Surgery Podiatrist	$4.7M	$23.5K
James Singer	IA	Retina Specialist (Ophthalmology) Physician	$4.1M	$0
Christopher Haupert	IA	Retina Specialist (Ophthalmology) Physician	$3.9M	$0

Nearby Providers

Other providers in the same ZIP code as Christopher Ronkar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mosaic	IA	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$177.4M
The Respite Connection, Inc.	IA	Community/Behavioral Health Agency	$0	$38.1M
Unitypoint At Home	IA	Durable Medical Equipment & Medical Supplies	$0	$16.5M
Unitypoint At Home	IA	Home Infusion Therapy Pharmacy	$0	$15.4M
New Beginnings Counseling Service, LLC	IA	Community/Behavioral Health Agency	$0	$6.3M
A-1 Iowa Dental PLLC	IA	Dentist	$0	$5.4M
Urbandale Community School District	IA	Local Education Agency (LEA)	$0	$4.4M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$3.9M
Acs Medical LLC	IA	Durable Medical Equipment & Medical Supplies	$0	$3.6M
Wellserve Health, Inc.	IA	Community/Behavioral Health Agency	$0	$2.8M

Christopher Ronkar — Billing Profile & Reimbursement Data

Sign up for Christopher Ronkar — Billing Profile & Reimbursement Data policy alerts

Christopher Ronkar — Billing Profile & Reimbursement Data

Sign up for Christopher Ronkar — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References